Abstract is: Herman Waldmann FRS FMedSci (born 27 February 1945) is a British immunologist known for his work on therapeutic monoclonal antibodies. As of 2013, he is Emeritus Professor of Pathology at the Sir William Dunn School of Pathology at the University of Oxford.
| human | Q5 |
| P268 | Bibliothèque nationale de France ID | 121061141 |
| P9594 | Bodleian Archives & Manuscripts person ID | 3856 |
| P6178 | Dimensions author ID | 0101043116.44 |
| P2070 | Fellow of the Royal Society ID | 12474 |
| P646 | Freebase ID | /m/0d9gyn |
| P269 | IdRef ID | 029432537 |
| P213 | ISNI | 0000000090487588 |
| P244 | Library of Congress authority ID | n79030016 |
| P2798 | Loop ID | 20084 |
| P8189 | National Library of Israel J9U ID | 987007272762905171 |
| P1006 | Nationale Thesaurus voor Auteursnamen ID | 074788078 |
| P496 | ORCID iD | 0000-0001-7519-6720 |
| P3368 | Prabook ID | 2348467 |
| P1153 | Scopus author ID | 7201458382 |
| 7202574587 | ||
| P214 | VIAF ID | 94354780 |
| P10832 | WorldCat Entities ID | E39PBJB8qrK69jHhJgB8WhD8YP |
| P166 | award received | Fellow of the Royal Society | Q15631401 |
| Fellow of the Academy of Medical Sciences | Q24081923 | ||
| P27 | country of citizenship | United Kingdom | Q145 |
| P69 | educated at | Sidney Sussex College | Q327116 |
| P108 | employer | University of Oxford | Q34433 |
| P734 | family name | Waldmann | Q524209 |
| Waldmann | Q524209 | ||
| Waldmann | Q524209 | ||
| P735 | given name | Herman | Q16276646 |
| Herman | Q16276646 | ||
| P1412 | languages spoken, written or signed | English | Q1860 |
| P463 | member of | Royal Society | Q123885 |
| P106 | occupation | researcher | Q1650915 |
| immunologist | Q12119633 | ||
| P21 | sex or gender | male | Q6581097 |
| Q34726892 | "Infectious" transplantation tolerance. |
| Q61651753 | (5) Induction of remission in systemic vasculitis with monoclonal antibody Campath-1H |
| Q27618561 | 1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen |
| Q61651681 | 1.9 Å structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen |
| Q38872469 | A Bacterial Artificial Chromosome Reporter System for Expression of the Human FOXP3 Gene in Mouse Regulatory T-Cells |
| Q92921975 | A Novel Role for Triglyceride Metabolism in Foxp3 Expression |
| Q57385312 | A Novel Strategy To Reduce the Immunogenicity of Biological Therapies |
| Q47939188 | A humanised therapeutic CD4 mAb inhibits TCR-induced IL-2, IL-4, and IL-10 secretion and expression of CD25, CD40L, and CD69. |
| Q38316946 | A humanized CD18 antibody can block function without cell destruction |
| Q61651734 | A humanized monovalent CD3 antibody which can activate homologous complement |
| Q81039592 | A key role for TGF-beta signaling to T cells in the long-term acceptance of allografts |
| Q43417655 | A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha |
| Q74515356 | A noncomitogenic CD2R monoclonal antibody induces apoptosis of activated T cells by a CD95/CD95-L-dependent pathway |
| Q47073100 | A novel role for Glucocorticoid-Induced TNF Receptor Ligand (Gitrl) in early embryonic zebrafish development |
| Q38576860 | A personal history of the CAMPATH-1H antibody |
| Q52852039 | A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. |
| Q61651826 | A rapid solid-phase enzyme-linked binding assay for screening monoclonal antibodies to cell surface antigens |
| Q34301539 | A repertoire of monoclonal antibodies with human heavy chains from transgenic mice |
| Q39560461 | A role for CD4+ but not CD8+ T cells in immunity to Schistosoma mansoni induced by 20 krad-irradiated and Ro 11-3128-terminated infections |
| Q61651690 | A role for Th2 cytokines in the suppression of CD8+ T cell-mediated graft rejection |
| Q39663583 | A role for regulatory T cells in acceptance of ESC-derived tissues transplanted across an major histocompatibility complex barrier |
| Q61651768 | A theoretical framework for self-tolerance and its relevance to therapy of autoimmune disease |
| Q60062004 | A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans |
| Q61651698 | AMPLIFICATION OF NATURAL REGULATORY IMMUNE MECHANISMS FOR TRANSPLANTATION TOLERANCE1 |
| Q51983574 | Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. |
| Q39251161 | Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice |
| Q42652346 | Activation rather than Foxp3 expression determines that TGF-β-induced regulatory T cells out-compete naïve T cells in dendritic cell clustering |
| Q61651712 | Active suppression induced by anti-CD4 |
| Q61651755 | Adoptive Suppression of Erythrocyte Autoantibodies in Lyt-2+Depleted Recipients |
| Q48576881 | Advantages of rat monoclonal antibodies |
| Q46485560 | Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. |
| Q46057969 | Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. |
| Q35022487 | Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? |
| Q61651652 | Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here? |
| Q54472663 | Allosuppression: evidence for the involvement of both “noncytotoxic” and cytotoxic T cells |
| Q37720518 | Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies |
| Q33639743 | Anti-CD3 treatment up-regulates programmed cell death protein-1 expression on activated effector T cells and severely impairs their inflammatory capacity |
| Q50726131 | Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. |
| Q61651678 | Anti-adhesion Molecule Therapy as an Interventional Strategy |
| Q73207762 | Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection |
| Q35624704 | Antibody-induced transplantation tolerance: the role of dominant regulation |
| Q69870076 | Antilymphocytic antibodies and marrow transplantation. VII. Two of nine monoclonal anti-Thy-1 antibodies used for pretreatment of donor marrow suppressed graft-versus-host reactions without added complement |
| Q61651686 | Apoptosis: potential for disease therapies |
| Q34262683 | Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance |
| Q53859655 | Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. |
| Q61651691 | Autologous Transplantation with CD52 Monoclonal Antibody-Purged Marrow for Acute Lymphoblastic Leukemia: Long-Term Follow-Up |
| Q72293447 | Availability of Campath-1 antibodies for bone marrow transplantation |
| Q39330381 | B cell activation |
| Q33561711 | Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T cells in rheumatoid arthritis |
| Q35927620 | Biomarkers of transplantation tolerance: more hopeful than helpful? |
| Q70043789 | Blocking of cytotoxic T cell function by monoclonal antibodies against the CD45 antigen (T200/leukocyte-common antigen) |
| Q47749207 | Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration |
| Q56873270 | Bone Marrow Transplantation for Patients with Chronic Myeloid Leukemia |
| Q40424968 | Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient |
| Q68242090 | Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse |
| Q68148434 | Bone marrow transplantation in beta-thalassemia major with prevention of graft-vs-host disease |
| Q74336481 | Bone marrow transplantation induces either clonal deletion or infectious tolerance depending on the dose |
| Q56904417 | Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplantation tolerance |
| Q61651679 | CAMPATH IH ALLOWS LOW-DOSE CYCLOSPORINE MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTS |
| Q61651665 | CAMPATH-1 antibodies in stem-cell transplantation |
| Q41053615 | CAMPATH-1 monoclonal antibodies in bone marrow transplantation. |
| Q33492953 | CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura |
| Q72814717 | CAMPATH-1H in inflammatory arthritis |
| Q61651700 | CAMPATH-1H in multiple sclerosis |
| Q36251298 | CAMPATH: from concept to clinic |
| Q61651706 | CD 4 and CD 8 monoclonal antibody therapy in canine renal allografts |
| Q38117284 | CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic |
| Q77952289 | CD4 T cells can reject major histocompatibility complex class I-incompatible skin grafts |
| Q61651715 | CD4 and CD8 monoclonal antibody therapy: Strategies to prolong renal allograft survival in the dog |
| Q61454994 | CD4 mAbs PREVENT PROGRESSION OF ALLOACTIVATED CD4+ T CELLS INTO THE S PHASE OF THE CELL CYCLE WITHOUT INTERFERING WITH EARLY ACTIVATION SIGNALS1 |
| Q70573365 | CD4 monoclonal antibodies in the preclinical dog renal allograft model |
| Q61651783 | CD4 monoclonal antibody pairs for immunosuppression and tolerance induction |
| Q55411821 | CD4+ T Cell Fate Decisions Are Stochastic, Precede Cell Division, Depend on GITR Co-Stimulation, and Are Associated With Uropodium Development. |
| Q73098784 | CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression |
| Q61651669 | CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells |
| Q36113098 | CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment |
| Q24681862 | CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells |
| Q41677608 | CD66 identifies a neutrophil-specific epitope within the hematopoietic system that is expressed by members of the carcinoembryonic antigen family of adhesion molecules |
| Q38063958 | CD73 and adenosine generation in the creation of regulatory microenvironments. |
| Q46317686 | CD8+ T-Cell depletion and rapamycin synergize with combined coreceptor/stimulation blockade to induce robust limb allograft tolerance in mice |
| Q33984208 | CD8+ lymphocytes do not mediate protection against acute superinfection 20 days after vaccination with a live attenuated simian immunodeficiency virus |
| Q35809302 | Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience |
| Q71331157 | Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors |
| Q42186381 | Campath-1H therapy in refractory ocular inflammatory disease |
| Q69521466 | Campath-1M--prophylactic use after kidney transplantation. A randomized controlled clinical trial |
| Q36672119 | Cell replacement therapy and the evasion of destructive immunity |
| Q71633436 | Cell- and tissue-specific expression of a human CD59 minigene in transgenic mice |
| Q39700853 | Cell-surface markers on haemopoietic precursors. Reagents for the isolation and analysis of progenitor cell subpopulations. |
| Q61651741 | Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia |
| Q24318606 | Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone |
| Q47622721 | Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome. |
| Q45056267 | Classical transplantation tolerance in the adult: the interaction between myeloablation and immunosuppression. |
| Q45159702 | Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation |
| Q33241067 | Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning |
| Q72142957 | Combined use of RS61443 with CD4 and CD8 MAbs to generate tolerance to skin xenografts from rat to mouse |
| Q61651667 | Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome |
| Q42940097 | Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. |
| Q61651743 | Complement activation by immunoglobulin does not depend solely on C1q binding |
| Q37773431 | Connecting the mechanisms of T-cell regulation: dendritic cells as the missing link |
| Q34331859 | Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. |
| Q61651719 | Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies |
| Q52244076 | Cooperation across the histocompatibility barrier. |
| Q42941110 | Cooperation across the histocompatibility barrier: H2d T cells primed to antigen in an H-2d environment can cooperate with H-2k B cells |
| Q91824677 | Coreceptor blockade targeting CD4 and CD8 allows acceptance of allogeneic human pluripotent stem cell grafts in humanized mice |
| Q61651651 | Correction: Resistance of regulatory T cells to glucocorticoid-induced TNFR family-related protein (GITR) duringPlasmodium yoelii infection |
| Q93591926 | Correction: Secreted and Transmembrane 1A Is a Novel Co-Stimulatory Ligand |
| Q61651806 | Corrigendum: Therapeutic potential of monovalent monoclonal antibodies |
| Q61651649 | Critical Influence of Natural Regulatory CD25+ T Cells on the Fate of Allografts in the Absence of Immunosuppression |
| Q27765998 | Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart |
| Q61651670 | Cutting Edge: Anti-CD154 Therapeutic Antibodies Induce Infectious Transplantation Tolerance |
| Q61651773 | DELAYED ALLOGRAFT REJECTION IN PRIMATES TREATED WITH ANTI-IL-2 RECEPTOR MONOCLONAL ANTIBODY CAMPATH-6 |
| Q61651672 | DOMINANT TOLERANCE AND LINKED SUPPRESSION INDUCED BY THERAPEUTIC ANTIBODIES DO NOT DEPEND ON FAS-FASL INTERACTIONS1 |
| Q61651771 | Delay in onset of insulitis in NOD mice following a single injection of CD 4 and CD8 antibodies |
| Q52059885 | Depletion of CD4+ and CD8+ cells eliminates immunologic memory of thyroiditogenicity in murine experimental autoimmune thyroiditis. |
| Q61651758 | Depletion of L3T4+ and Lyt-2+ cells by rat monoclonal antibodies alters the development of adoptively transferred experimental autoimmune thyroiditis |
| Q61651807 | Detection of monoclonal antibodies against cell surface antigens: the use of antiglobulins coupled to red blood cells |
| Q61651656 | Development and clinical use of CAMPATH® 1H |
| Q41894585 | Dickkopf-3, a tissue-derived modulator of local T-cell responses |
| Q43977064 | Different roles for L3T4+ and Lyt 2+ T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system |
| Q54281058 | Direct antibody rosette-forming reactions using monoclonal markers of lymphocyte subpopulations. Methodology and applications illustrated by investigations with rat pan-T antibodies of the CAMPATH series. |
| Q40837850 | Directed differentiation of dendritic cells from mouse embryonic stem cells. |
| Q45842663 | Do L3T4+ T cells act as effector cells in protection against influenza virus infection |
| Q36061019 | Dominant tolerance: activation thresholds for peripheral generation of regulatory T cells |
| Q61651663 | Dominant transplantation tolerance impairs CD8+ T cell function but not expansion |
| Q35538145 | Dominant transplantation tolerance. Opinion |
| Q35971446 | Donor-specific transplantation tolerance: the paradoxical behavior of CD4+CD25+ T cells |
| Q47625189 | Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries |
| Q61651627 | Drug minimization in transplantation |
| Q61651760 | EFFECT OF GRAFT PERFUSION WITH TWO CD45 MONOCLONAL ANTIBODIES ON INCIDENCE OF KIDNEY ALLOGRAFT REJECTION |
| Q61651682 | EX VIVO DEPLETION OF T CELLS FROM BONE MARROW GRAFTS WITH CAMPATH-1 IN ACUTE LEUKEMIA |
| Q61651638 | Ectopic Transplantation of Tissues Under the Kidney Capsule |
| Q81311194 | Ectopic transplantation of tissues under the kidney capsule |
| Q69737033 | Effect of CD4 monoclonal antibody in vivo on lesion development, delayed-type hypersensitivity and interleukin 3 production in experimental murine cutaneous leishmaniasis |
| Q69597064 | Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype |
| Q70507731 | Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans |
| Q61651721 | Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen |
| Q54469837 | Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). |
| Q40964758 | Elimination of the immunogenicity of therapeutic antibodies |
| Q36693370 | Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance |
| Q35868730 | Embryonic stem cells and the challenge of transplantation tolerance |
| Q40482532 | Embryonic stem cells: a novel source of dendritic cells for clinical applications. |
| Q37370557 | Embryonic stem cells: overcoming the immunological barriers to cell replacement therapy |
| Q36914616 | Embryonic stem cells: protecting pluripotency from alloreactivity |
| Q61651680 | Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies |
| Q34999729 | Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade |
| Q61651631 | Enhanced murine contact hypersensitivity by depletion of endogenous regulatory T cells in the sensitization phase |
| Q40468339 | Enhanced production of IL-10 by dendritic cells deficient in CIITA. |
| Q44267619 | Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody |
| Q45749057 | Epstein-Barr virus (EBV) associated B-cell lymphoproliferative disease following HLA identical sibling marrow transplantation for aplastic anaemia in a patient with an EBV seronegative donor |
| Q61651831 | Evidence for the inactivation of precursor B cells in high dose unresponsiveness |
| Q61651794 | Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation |
| Q64381622 | Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect |
| Q73849702 | Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype |
| Q45004391 | Exacerbation of delayed-type hypersensitivity responses in EBV-induced gene-3 (EBI-3)-deficient mice |
| Q61053497 | Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation |
| Q37712267 | Expansion of Foxp3(+) T-cell populations by Candida albicans enhances both Th17-cell responses and fungal dissemination after intravenous challenge. |
| Q53637597 | Exploiting tolerance processes in transplantation. |
| Q34621366 | Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells |
| Q77320391 | Expression of murine IL-12 is regulated by translational control of the p35 subunit |
| Q74165004 | Extrathymic signals regulate the onset of T cell repertoire selection |
| Q73821426 | Fas-independent apoptosis of activated T cells induced by antibodies to the HLA class I alpha1 domain |
| Q61651654 | Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia |
| Q53530309 | Fc-disabled anti-mouse CD40L antibodies retain efficacy in promoting transplantation tolerance. |
| Q51778586 | Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. |
| Q57226615 | Foxp3 T reg cells control psoriasiform inflammation by restraining an IFN-I-driven CD8 T cell response |
| Q37624347 | Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. |
| Q36305999 | Foxp3 expression is required for the induction of therapeutic tissue tolerance |
| Q28305809 | From Laboratory to Clinic : The Story of CAM PA TH-1 |
| Q44098687 | Functional analysis of T lymphocyte subsets in antiviral host defense. |
| Q38787481 | Gene expression in the Gitr locus is regulated by NF-κB and Foxp3 through an enhancer |
| Q28188408 | Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation |
| Q47644661 | Generation of anergic and regulatory T cells following prolonged exposure to a harmless antigen |
| Q61651632 | Generation of anti-inflammatory adenosine byleukocytes is regulated by TGF-β |
| Q53503551 | Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells. |
| Q61651640 | Genetic Modification of Dendritic Cells Through the Directed Differentiation of Embryonic Stem Cells |
| Q36944524 | Genetic modification of dendritic cells through the directed differentiation of embryonic stem cells |
| Q61651628 | Guiding Postablative Lymphocyte Reconstitution as a Route Toward Transplantation Tolerance |
| Q61651673 | HIGH DOSE BONE MARROW TRANSPLANTATION INDUCES DELETION OF ANTIGEN-SPECIFIC T CELLS IN A FAS-INDEPENDENT MANNER1 |
| Q52272254 | Haemopoietic progenitor cell heterogeneity revealed by a single monoclonal antibody, YW 13.1.1. |
| Q38201272 | Harnessing FOXP3+ regulatory T cells for transplantation tolerance. |
| Q37100901 | Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity |
| Q61053494 | High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution |
| Q40984657 | High level transcription of the complement regulatory protein CD59 requires an enhancer located in intron 1. |
| Q56907926 | How do monoclonal antibodies induce tolerance? A role for infectious tolerance? |
| Q40261924 | How many T cells help one B cell? |
| Q61651633 | Human CD3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance |
| Q61651703 | Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement |
| Q90420157 | Human Monoclonal Antibodies: The Benefits of Humanization |
| Q42939256 | Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. |
| Q38137821 | Human monoclonal antibodies: the residual challenge of antibody immunogenicity |
| Q67672469 | Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers |
| Q60062009 | Humanised monoclonal antibody therapy for rheumatoid arthritis |
| Q39452477 | Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease |
| Q43503425 | Humanized monoclonal antibody treatment in rheumatoid arthritis |
| Q39556005 | Hybrid antibodies for therapy |
| Q40872798 | IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. |
| Q28510654 | IL-10-conditioned dendritic cells, decommissioned for recruitment of adaptive immunity, elicit innate inflammatory gene products in response to danger signals |
| Q61440325 | IMMUNE RECONSTITUTION AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION DEPLETED OF T CELLS |
| Q61651787 | Identification of cells of the human mononuclear phagocyte system with rat monoclonal antibodies |
| Q61651800 | Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies |
| Q34524237 | Identification of regulatory T cells in tolerated allografts |
| Q36593774 | Immune privilege induced by regulatory T cells in transplantation tolerance |
| Q46177428 | Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome |
| Q36425444 | Immunoglobulin heavy chain locus of the rat: striking homology to mouse antibody genes |
| Q61651809 | Immunohistological screening in the selection of monoclonal antibodies: the use of isotype-specific antiglobulins |
| Q57899398 | Immunological tolerance |
| Q54033319 | Immunosuppression of canine renal allograft recipients by CD4 and CD8 monoclonal antibodies. |
| Q72751213 | Immunosuppression with monoclonal antibodies. A model to determine the rules for effective serotherapy |
| Q61651674 | Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G |
| Q45032703 | Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. |
| Q47741445 | Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection |
| Q44382145 | In vitro and in vivo depletion of T cells. |
| Q61651693 | In vivo 'Purging' of residual disease in CLL with Campath-1H |
| Q44097232 | In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation |
| Q72992312 | In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation |
| Q33987464 | In vivo kinetics of GITR and GITR ligand expression and their functional significance in regulating viral immunopathology |
| Q61651704 | In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium |
| Q68146351 | In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation |
| Q48013835 | Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab |
| Q36786632 | Induced Foxp3(+) T Cells Colonizing Tolerated Allografts Exhibit the Hypomethylation Pattern Typical of Mature Regulatory T Cells |
| Q38977789 | Induction of Immunological Tolerance as a Therapeutic Procedure |
| Q61651655 | Induction of Immunological Tolerance/Hyporesponsiveness in Baboons with a Nondepleting CD4 Antibody |
| Q61651641 | Induction of Regulatory T Cells and Dominant Tolerance by Dendritic Cells Incapable of Full Activation |
| Q41965507 | Induction of classical transplantation tolerance in the adult |
| Q34380578 | Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby. |
| Q47644499 | Induction of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants |
| Q43419298 | Induction of tolerance by monoclonal antibody therapy |
| Q55042547 | Induction of tolerance in peripheral T cells with monoclonal antibodies. |
| Q36563558 | Infectious tolerance and the long-term acceptance of transplanted tissue |
| Q37246191 | Infectious tolerance via the consumption of essential amino acids and mTOR signaling |
| Q55068093 | Infectious tolerance. |
| Q96680975 | Infectious tolerance. What are we missing? |
| Q37786737 | Infectious tolerance: therapeutic potential |
| Q40680962 | Influence of the major histocompatibility complex on lymphocyte interactions in antibody formation |
| Q34428346 | Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes |
| Q93627193 | Interaction of rat monoclonal antibodies with human killer cells |
| Q61651811 | Interaction of rat monoclonal antibodies with human killer cells (K cells) |
| Q61651828 | Interactions between T and B Cells: A Review |
| Q61651707 | Isolation and expression of cDNA encoding the canine CD4 and CD8α antigens |
| Q61651789 | Isolation of low-frequency class-switch variants from rat hybrid myelomás |
| Q28750209 | Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target |
| Q70046698 | L3T4 and Lyt-2 T cells are both involved in the generation of low-dose streptozotocin-induced diabetes in mice |
| Q69891851 | Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia |
| Q38257659 | Limiting dilution analysis of cells of the immune system II: What can be learnt? |
| Q61651813 | Limiting dilution analysis of the cells of immune system I. The clonal basis of the immune response |
| Q43863962 | Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen |
| Q77620004 | Linked suppression of skin graft rejection can operate through indirect recognition |
| Q60062007 | Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy |
| Q55641712 | Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis. |
| Q35008814 | Loss of the TGFβ-activating integrin αvβ8 on dendritic cells protects mice from chronic intestinal parasitic infection via control of type 2 immunity. |
| Q43654692 | Low dose unresponsiveness with a thymus independent antigen |
| Q51987968 | Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. |
| Q33502949 | MS4A4B is a GITR-associated membrane adapter, expressed by regulatory T cells, which modulates T cell activation |
| Q47636232 | Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex vivo and in vivo T-cell depletion. |
| Q39775657 | Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells |
| Q36888736 | Mechanism of recovery from acute virus infection: treatment of lymphocytic choriomeningitis virus-infected mice with monoclonal antibodies reveals that Lyt-2+ T lymphocytes mediate clearance of virus and regulate the antiviral antibody response |
| Q54193778 | Mechanisms in CD4 antibody-mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T cells. |
| Q61651646 | Mechanisms of Antibody Immunotherapy on Clonal Islet Reactive T Cells |
| Q38513448 | Mechanisms of immunological tolerance |
| Q61651775 | Mechanisms of monoclonal antibody-facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination |
| Q41326954 | Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. |
| Q49403463 | Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization |
| Q35703967 | Monoclonal antibodies as agents to reinduce tolerance in autoimmunity. |
| Q39555999 | Monoclonal antibodies for immunosuppression |
| Q39678713 | Monoclonal antibodies for the depletion of specific subpopulations of lymphocytes. |
| Q40780243 | Monoclonal antibodies for the induction of transplantation tolerance |
| Q54423268 | Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo. |
| Q40891060 | Monoclonal antibodies for the therapeutic induction of tolerance |
| Q61651823 | Monoclonal antibodies to haemopoietic cells |
| Q59074162 | Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance |
| Q39713867 | Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. |
| Q38562337 | Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. |
| Q28144207 | Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis |
| Q61651745 | Monoclonal-Antibody Therapy in Systemic Vasculitis |
| Q43507473 | Monoclonals and marrow transplants |
| Q61651815 | Monocytic origin of foam cells in human atherosclerotic plaques |
| Q40655074 | Monogamous T helper cell |
| Q34395747 | Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia |
| Q37073761 | Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes |
| Q28513895 | Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells |
| Q46661656 | Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts |
| Q47728793 | Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis |
| Q47343514 | Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis |
| Q55384323 | Non-Invasive Multiphoton Imaging of Islets Transplanted Into the Pinna of the NOD Mouse Ear Reveals the Immediate Effect of Anti-CD3 Treatment in Autoimmune Diabetes. |
| Q37434184 | Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease |
| Q34100538 | Nutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment |
| Q58202157 | P1. Immunoablation with t cell depleted autologous peripheral blood stem cell rescue produces complete remission in thrombocytopenic purpura (TTP) recidivant and refractory to standard treatment |
| Q61651684 | PHASE I STUDY OF AN ENGINEERED AGLYCOSYLATED HUMANIZED CD3 ANTIBODY IN RENAL TRANSPLANT REJECTION1 |
| Q43199221 | Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice |
| Q69242474 | Pathogenic mechanisms in murine autoimmune thyroiditis: short- and long-term effects of in vivo depletion of CD4+ and CD8+ cells |
| Q43980367 | Pediatric immunohematopoietic stem cell transplantation at a tertiary care center in Cape Town |
| Q61651763 | Peripheral tolerance mechanisms prevent the development of autoreactive T cells in chimeras grafted with two minor incompatible thymuses |
| Q45050594 | Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. |
| Q44071979 | Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). |
| Q68898457 | Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation |
| Q50968365 | Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. |
| Q33906407 | Posttranscriptional regulation of IL-10 gene expression through sequences in the 3'-untranslated region. |
| Q48087197 | Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis |
| Q61651675 | Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity |
| Q50983902 | Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients. |
| Q61651723 | Prevention of Diabetes but not Insulitis in NOD Mice Injected with Antibody to CD4 |
| Q60062005 | Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H |
| Q40603756 | Probing dendritic cell function by guiding the differentiation of embryonic stem cells |
| Q73694942 | Prope tolerance with induction using Campath 1H and low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients |
| Q61651688 | Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients |
| Q61651840 | Properties of educated T cells. The ability of educated T cells to facilitate the immune response to non-cross-reacting antigensin vitro |
| Q70273669 | Prophylactic use of an antilymphocyte monoclonal antibody following renal transplantation: a randomized controlled trial |
| Q95055682 | Prospects for ensuring acceptance of ES cell-derived tissues |
| Q59005723 | Protection and privilege |
| Q61651685 | Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis |
| Q68719546 | Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms |
| Q61651778 | REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H |
| Q45129358 | Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia |
| Q69911893 | Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series |
| Q43725422 | Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation |
| Q71250697 | Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection |
| Q44517418 | Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation |
| Q61651657 | Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity |
| Q34241129 | Regulating the immune response to transplants. a role for CD4+ regulatory cells? |
| Q61651642 | Regulation and privilege in transplantation |
| Q53530470 | Regulation and privilege in transplantation tolerance. |
| Q34101903 | Regulation of CD40 function by its isoforms generated through alternative splicing |
| Q41049616 | Regulation of IL-18 (IFN-gamma-inducing factor) gene expression |
| Q61651634 | Regulation of the immune response |
| Q58335878 | Regulatory T Cells Promote Apelin-Mediated Sprouting Angiogenesis in Type 2 Diabetes |
| Q33195020 | Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms |
| Q35703532 | Regulatory T cells and organ transplantation |
| Q43563597 | Regulatory T cells and transplantation tolerance. |
| Q35069619 | Regulatory T cells in the induction and maintenance of peripheral transplantation tolerance |
| Q61651648 | Regulatory T cells in transplantation |
| Q31035510 | Regulatory T cells overexpress a subset of Th2 gene transcripts |
| Q47737273 | Regulatory T cells: context matters |
| Q26865816 | Regulatory cells and transplantation tolerance |
| Q48029668 | Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. |
| Q41748357 | Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies. |
| Q70397463 | Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes |
| Q28266531 | Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement |
| Q34792489 | Reprogramming the immune system |
| Q84468889 | Reprogramming the immune system |
| Q35595898 | Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies |
| Q37835921 | Reprogramming the immune system for tolerance with monoclonal antibodies |
| Q36514566 | Reprogramming the immune system using antibodies. |
| Q72814712 | Reprogramming the immune system: a possible therapeutic approach to established autoimmune disease |
| Q34793904 | Reprogramming the immune system: co-receptor blockade as a paradigm for harnessing tolerance mechanisms |
| Q37510930 | Reshaping a therapeutic CD4 antibody |
| Q28290936 | Reshaping human antibodies for therapy |
| Q48020021 | Resistance of regulatory T cells to glucocorticoid-induced [corrected] TNFR family-related protein (GITR) during Plasmodium yoelii infection. |
| Q54356874 | Resistance to experimental autoimmune thyroiditis: L3T4+ cells as mediators of both thyroglobulin-activated and TSH-induced suppression. |
| Q43577899 | Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality |
| Q67995060 | Reversal of allograft rejection using the monoclonal antibody, Campath-1G |
| Q45756933 | Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. |
| Q61651643 | SAGE Analysis of Cell Types Involved in Tolerance Induction |
| Q36944558 | SAGE analysis of cell types involved in tolerance induction |
| Q61651797 | SKIN ALLOGRAFT REJECTION BY L3/t4+ AND LYT-2+ T CELL SUBESTS |
| Q61651694 | STRAIN VARIATION IN SUSCEPTIBILITY TO MONOCLONAL ANTIBODY-INDUCED TRANSPLANTATION TOLERANCE1 |
| Q31139507 | Secreted and transmembrane 1A is a novel co-stimulatory ligand |
| Q61651819 | Segregation of mouse hemopoietic progenitor cells using the monoclonal antibody, YBM/42 |
| Q71222857 | Selective isolation of murine erythropoietin-responsive progenitor cells (CFU-E) with monoclonal antibodies |
| Q59058139 | Self tolerance is H–2-restricted |
| Q34663686 | Semi-specific immuno-absorption and monoclonal antibody therapy in ANCA positive vasculitis: experience in four cases |
| Q70240520 | Separation of hemopoietic cells from adult mouse marrow by use of monoclonal antibodies |
| Q48329836 | Sequence of a rat immunoglobulin gamma 2c heavy chain constant region cDNA: extensive homology to mouse gamma 3. |
| Q35613442 | Serial analysis of gene expression provides new insights into regulatory T cells |
| Q58711931 | Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells |
| Q71801217 | Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines |
| Q37043712 | Special regulatory T cell review: The suppression problem! |
| Q45047397 | Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase |
| Q70213447 | Specificity of monoclonal antibody Campath-1 |
| Q70573336 | Stability of tolerance in mice generated by CD4 and CD8 monoclonal antibody treatment: cell transfer experiments |
| Q51835805 | Stable lines of genetically modified dendritic cells from mouse embryonic stem cells. |
| Q27649488 | Structural basis for ligand-mediated mouse GITR activation |
| Q61651725 | Structural motifs involved in human IgG antibody effector functions |
| Q30792919 | Structure and chromosomal location of mouse and human CD52 genes |
| Q48063953 | Structure and chromosomal location of the mouse interleukin-12 p35 and p40 subunit genes |
| Q41863626 | Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis |
| Q70832742 | Substantial peripheral T-cell depletion before grafting is beneficial in islet transplantation |
| Q36479748 | Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine |
| Q61651798 | Successful haploidentical mismatched bone marrow transplantation in severe combined immunodeficiency: T cell removal using CAMPATH-I monoclonal antibody and E-rosetting |
| Q43913093 | Suppression in murine experimental autoimmune thyroiditis: in vivo inhibition of CD4+ T cell-mediated resistance by a nondepleting rat CD4 monoclonal antibody |
| Q61651695 | Sustained remission of severe resistant autoimmune neutropenia with Campath-1H |
| Q35237468 | Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance |
| Q61651792 | Synergistic complement lysis by monoclonal antibodies to the human leukocyte common antigen requires both the classical and alternative pathways |
| Q45832629 | Synergistic monoclonal antibodies for in vitro immunomodulation of dog islets |
| Q61651842 | T Cell-dependent Mediator in the Immune Response |
| Q61651838 | T cell dependence of B cell unresponsivenessin vitro |
| Q46691197 | T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease |
| Q68133082 | T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation |
| Q71384543 | T cell regulation in adult transplantation tolerance |
| Q61651696 | T cell sensitivity to HLA class I-mediated apoptosis is dependent on interleukin-2 and interleukin-4 |
| Q45941862 | T cell suppression in transplantation tolerance through linked recognition. |
| Q61651658 | T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated don |
| Q61651659 | T-cell depletion with Campath-1H 'in the bag' for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival |
| Q43752662 | T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies |
| Q61651705 | T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse |
| Q37916936 | TGF-β in transplantation tolerance |
| Q41897840 | TGF-β-mediated Foxp3 gene expression is cooperatively regulated by Stat5, Creb, and AP-1 through CNS2. |
| Q61651803 | THERAPEUTIC POTENTIAL OF MONOCLONAL ANTIBODIES TO THE LEUKOCYTE-COMMON ANTIGEN |
| Q61651701 | TOLERANCE AND SUPPRESSION IN A PRIMED IMMUNE SYSTEM1 |
| Q53385340 | Th17 cells induce a distinct graft rejection response that does not require IL-17A. |
| Q61651748 | The CAMPATH-1 antigen (CDw52) |
| Q35163031 | The CD59 antigen--a multifunctional molecule |
| Q42318231 | The Induction and Maintenance of Transplant Tolerance Engages Both Regulatory and Anergic CD4+ T cells |
| Q39526580 | The Influence of the Major Histocompatibility Complex on the Function of T-Helper Cells in Antibody Formation |
| Q49630753 | The Role of Lipid Metabolism in T Lymphocyte Differentiation and Survival |
| Q68185856 | The anti-IL-2 receptor monoclonal antibody YTH-906 in liver transplantation |
| Q61651821 | The characterisation of monoclonal antibodies against haemopoietic cells: Comparison of an immunoperoxidase method with fluorescence activated cell sorting |
| Q61651738 | The development of insulin-dependent diabetes mellitus in non-obese diabetic mice: the role of CD4+ and CD8+ T cells |
| Q41652733 | The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. |
| Q43635761 | The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. |
| Q33339027 | The effect of treatment with Campath-1H in patients with autoimmune cytopenias |
| Q61651837 | The failure to show a necessary role for C3 in thein vitro antibody response |
| Q41575430 | The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties |
| Q28278597 | The human interleukin 18 gene IL18 maps to 11q22.2-q22.3, closely linked to the DRD2 gene locus and distinct from mapped IDDM loci |
| Q36357164 | The immunogenicity of chimeric antibodies |
| Q61651766 | The improved lytic function andin vivo efficacy of monovalent monoclonal CD3 antibodies |
| Q43414853 | The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies |
| Q38595843 | The influence of thymus on the development of MHC restrictions exhibited by T-helper cells |
| Q61651751 | The involvement of Ly 2+ T cells in beta cell destruction |
| Q35206940 | The new immunosuppression |
| Q36352239 | The new immunosuppression: intervention at the dendritic cell-T-cell interface. |
| Q61651660 | The new immunosuppression: just kill the T cell |
| Q35015109 | The nuclear orphan receptor Nr4a2 induces Foxp3 and regulates differentiation of CD4+ T cells |
| Q50987847 | The plasticity and stability of regulatory T cells. |
| Q61651781 | The potential of hybrid antibodies secreted by hybrid-hybridomas in tumour therapy |
| Q56420835 | The relationship between pityriasis rubra pilaris and inflammatory arthritis: Case report and response of the arthritis to anti-tumor necrosis factor immunotherapy |
| Q68127605 | The repopulation capacity of bone marrow grafts following pretreatment with monoclonal antibodies against T lymphocytes in rhesus monkeys |
| Q42514630 | The role of Sp1 and NF-kappa B in regulating CD40 gene expression |
| Q44587253 | The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice. |
| Q68200078 | The use of monoclonal antibodies against activated human T cells following renal allografting in the baboon |
| Q61651728 | The use of monoclonal antibodies to achieve immunological tolerance |
| Q40767477 | The use of monoclonal antibodies to achieve immunological tolerance. |
| Q40695890 | The vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine intranasal model |
| Q50766232 | The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. |
| Q34360541 | Therapeutic approaches for transplantation. |
| Q34441123 | Therapeutic aspects of tolerance. |
| Q69976117 | Therapeutic potential of monoclonal antibodies to the leucocyte common antigen |
| Q59057896 | Therapeutic potential of monovalent monoclonal antibodies |
| Q44693815 | Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes |
| Q59082223 | Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo |
| Q41871994 | Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential |
| Q77436804 | Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function |
| Q28509998 | Tmem176B and Tmem176A are associated with the immature state of dendritic cells |
| Q61651637 | Tolerance can be infectious |
| Q61651732 | Tolerance in the mouse to major histocompatibility complex-mismatched heart allografts, and to rat heart xenografts, using monoclonal antibodies to CD4 and CD8 |
| Q72057305 | Tolerance induction in concordant heart-xenografted mice by CD4 and CD8 monoclonal antibodies |
| Q69136267 | Tolerance induction in the adult using monoclonal antibodies to CD4, CD8, and CD11a (LFA-1) |
| Q40507187 | Tolerance induction in the adult: 'danger' at Le Bischenberg. |
| Q39092500 | Tolerance induction to human stem cell transplants with extension to their differentiated progeny |
| Q77370091 | Tolerance induction with CD4 monoclonal antibodies |
| Q61651729 | Tolerance to IDDM Induced by CD4 Antibodies in Nonobese Diabetic Mice is Reversed by Cyclophosphamide |
| Q42938072 | Tolerance to rat monoclonal antibodies. Implications for serotherapy |
| Q37780677 | Tolerance: an overview and perspectives |
| Q51572910 | Tolerogenicity is not an absolute property of a dendritic cell. |
| Q41694031 | Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement |
| Q61651635 | Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients |
| Q49151897 | Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis |
| Q61651661 | Transplantation |
| Q61651676 | Transplantation |
| Q61651709 | Transplantation |
| Q48854818 | Transplantation tolerance: the big picture. Where do we stand, where should we go? |
| Q61651664 | Transplantation—caught in the crossfire! |
| Q73029044 | Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies |
| Q33656364 | Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells |
| Q61851839 | Unrelated donor bone marrow transplant in childhood ALL. The role of T-cell depletion |
| Q61651702 | Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission |
| Q61651697 | Use of Ceprate CD34-positive selection system for depletion of T cells in allogeneic transplantation |
| Q40573339 | What can be done to prevent graft versus host disease? |
| Q37787584 | mTOR signalling and metabolic regulation of T cell differentiation |
| Arabic (ar / Q13955) | هيرمان والدمان | wikipedia |
| Herman Waldmann | wikipedia |
Search more.